Aging results in a redistribution of polyunsaturated fatty acids (PUFAs) in myocardial phospholipids. In particular, a selective loss of linoleic acid (18:2n6) with reciprocal increases of long-chain PUFAs (eg, arachidonic and docosahexaenoic acids) in the mitochondrial phospholipid cardiolipin correlates with cardiac mitochondrial dysfunction and contractile impairment in aging and related pathologies. In this study, we demonstrate a reversal of this aged-related PUFA redistribution pattern in cardiac mitochondria from aged (25 months) C57Bl/6 mice by inhibition of delta-6 desaturase, the rate limiting enzyme in long-chain PUFA biosynthesis. Interestingly, delta-6 desaturase inhibition had no effect on age-related mitochondrial respiratory dysfunction, H 2 O 2 release, or lipid peroxidation but markedly attenuated cardiac dilatation, hypertrophy, and contractile dysfunction in aged mice. Taken together, our studies indicate that PUFA metabolism strongly influences phospholipid remodeling and cardiac function but dissociates these processes from mitochondrial respiratory dysfunction and oxidant production in the aged mouse heart.
A gINg is associated with progressive cardiac hypertrophy and contractile impairment and is a primary risk factor for heart failure in humans (1, 2) . Deterioration of cardiac mitochondrial function, manifesting as impaired bioenergetics or increased production of reactive oxygen species (ROS), is thought to be a primary contributor to myocardial aging and associated pathologies (3) (4) (5) . However, the extent, mechanisms, and pathophysiological importance of mitochondrial dysfunction in cardiac aging remain controversial.
The fatty acid composition of cardiac membrane phospholipids changes with advancing age (6) (7) (8) (9) and is highly predictive of maximal life span across mammalian species (10) (11) (12) . Interestingly, across nearly all experimental models and species, the predominant compositional change is a proportional loss of the essential polyunsaturated fatty acid (PUFA) linoleic acid (18:2n6; LA), matched by increases in the long-chain highly unsaturated fatty acids arachidonic acid (20:4n6; AA) or docosahexaenoic acid (22:6n3; DHA). This pattern of remodeling is particularly evident in the mitochondrial phospholipid cardiolipin, which is normally highly enriched with LA in the mammalian heart, where it plays an important role in supporting mitochondrial function (13) . An exchange of LA for long-chain PUFAs in cardiac cardiolipin occurs with aging and related pathologies and has been suggested as a potential contributor to mitochondrial dysfunction, oxidative stress, and contractile impairment associated with these conditions (8, (14) (15) (16) (17) . However, causal links between cardiolipin remodeling and these phenomena have remained unclear due to the absence of experimental studies demonstrating reversal of the process in an aging model.
In the present study, we hypothesized that inhibition of delta-6 desaturase (D6D), the rate-limiting enzyme in PUFA biosynthesis (Figure 1 ), would reverse age-related changes in cardiolipin composition by preserving myocardial LA bioavailability and reducing endogenous biosynthesis of AA and DHA. Young and old C57Bl/6 mice were treated with an orally active selective D6D inhibitor or no drug for 4 weeks, followed by examination of cardiac mitochondrial phospholipid composition, respiratory function, ROS release, and lipid peroxidation, along with assessment of myocardial structure and function. Our studies reveal a pivotal effect of essential PUFA metabolism on cardiolipin composition, hypertrophy, and contractile function in the aged heart but dissociate these phenomena from changes in cardiac mitochondrial respiratory function, ROS release, and lipid peroxidation.
Methods

Animal Model of Cardiac Aging
To determine the nature and extent of cardiolipin remodeling in the C57Bl/6 mouse model of aging, heart tissues were obtained from 4-and 24-month-old mice (n = 4/ group) from the National Institute on Aging tissue bank for assessment of phospholipid fatty acid composition. Following confirmation of the signature remodeling pattern reported in aged rats (8) and humans with heart failure (14) (Supplementary Table 1) , male C57BL/6 mice were obtained from the National Institute on Aging aging colony at 4 months (young; n = 12) and 24 months (old; n = 12) of age for experimental studies. All mice were maintained on standard chow ad libitum (Harlan Teklad 2918) for 4 weeks prior to being randomly assigned to D6D inhibition or control groups (n = 6/group).
Inhibition of D6D In Vivo
To inhibit systemic D6D activity in vivo, mice were administered the potent, orally active D6D inhibitor SC-26196 (Biofine, Inc., Blaine, WA), at a dose previously reported to selectively inhibit D6D enzyme activity with no effect on other desaturase enzymes in mice in vivo (100 mg/kg/d mixed in chow) (18) for 4 weeks based on daily food consumption records taken more than 3-4 weeks prior to treatment. This inhibitor compound has been shown to selectively inhibit D6D in rat liver microsomes (18) , Hepg2 hepatocytes, and multiple human cell types in vitro and elicit marked reductions in D6D product:precursor ratios (eg, 20:4n6/18:2n6) in tissue phospholipids reflective of D6D activity in vivo when administered to mice orally at the dose used in this study. Following the 4-week experimental period, animals were deeply anesthetized with 100 mg/kg sodium pentobarbital and sacrificed by midline thoracotomy and removal of the heart. All procedures were approved by the Colorado State University Care and Use Committee and conform to the Guide for the Care and use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Mitochondrial Isolation
Mitochondria were freshly isolated from ~75-90 mg of heart tissue in cold Chappell-Perry buffer consisting of (in mM) KCl (100), MOPS (50), EgTA (1), MgSO 4 ·7H 2 O (5), and ATP (1), pH 7.4 (with KOH) by standard differential centrifugation methods as previously described with minor modifications (14) . To determine if aging or D6D activity differentially affects the two spatially distinct mitochondrial subpopulations present in cardiomyocytes, both subsarcolemmal mitochondria (SSM) and intermyofibrillar mitochondria (IFM) were isolated, using trypsin to dissociate IFM from myofibrillar proteins. Details regarding the mitochondrial isolation procedure are included in Supplementary Methods.
Fatty Acid Composition of tissue and Mitochondrial Phospholipids
Lipids were extracted from heart tissue (~20 mg) or serum (50 μL) by homogenization in 800 or 600 μL of methanol, respectively. The nonphospholipid fraction was pelleted by centrifugation at 1,000g for 5 minutes at room temperature. The supernatant was added to 25 μL of 25% sodium methoxide solution and incubated at room temperature for 3 minutes to generate fatty acid methyl esters. The reaction was stopped by adding 75 μL methanolic HCl (3N). Fatty acid methyl esters were extracted by adding 700 μL of hexane to each sample. Samples were vortexed for 30 seconds, and the top hexane layer (containing fatty acid methyl esters) was transferred to gas chromatography vials and dried down under a stream of nitrogen gas. Serum samples were resuspended in 50 μL of hexane, and heart samples were resuspended in 100 μL of hexane to achieve optimum peak resolution. gas chromatography analysis was performed Figure 1 . Central role of delta-6 desaturase (D6D) in polyunsaturated fatty acid (PUFA) metabolism. D6D catalyzes rate limiting steps in the production of long-chain PUFAs from linoleic (18:2n6, LA) and linolenic (18:3n3) acids obtained in the diet. Fatty acid nomenclature: C:XnY, where C = number of carbons, X = number of double bonds, and Y = location of first double bond from the omega carbon. Double arrows indicate additional reactions catalyzed by elongase enzymes (E), delta-5 desaturase (D5D), and peroxisomal fatty acid β-oxidation (PβOx). LA, arachidonic acid (AA), and docosahexaenoic acid (DHA; shaded) are the only PUFAs that readily accumulate in cardiac phospholipids to >2% of total fatty acids in humans and rats. Underscored fatty acids are pathway products or precursors routinely used to estimate D6D activity in tissues. AA serves as the substrate for lipoxygenase (LOX), cyclooxygenase (COX), and CYP450 epoxygenase enzymes or may be nonenzymatically oxidized by reactive oxygen species (ROS), generating an array of bioactive eicosanoid species.
using an Agilent Technologies DB-225 30 m × 0.250 mm × 0.25 μm column (model 122-2232, J&W Scientific) on an Agilent 6890 Series gas Chromatographer with a flame ionization detector, with a flow rate of 1.7 mL/min and split ratio of 15:1 in 25 minutes. The initial temperature of the oven was 120°C with an initial ramp temperature of 10°C/min for 8 minutes, then 2.5°C/min for 4 minutes and held at 210°C for the remaining 6 minutes for a total run time of 20 minutes. The inlet split ratio was 15:1 with the column at constant flow and an initial flow, pressure, and velocity at 1.8 mL/min, 23.59 psi, and 42 cm/s, respectively. Lipids form hearts and mitochondria (0.5 mg protein) were extracted in 2:1 chloroform:methanol and then dried down and resuspended in hexane for separation of individual phospholipid classes by normal phase liquid chromatography (Agilent Zorbax Rx-Sil column, 4.6 × 250 mm, 5 μm). A mobile phase gradient of hexane:isopropanol:0.3 mM potassium acetate (pH 7.0):acetic acid (424:566:10:0.1) to hexane:isopropanol:5.0 mM potassium acetate (pH 7.0):acetic acid (385:515:100:1) in 6 minutes and then held for 5 minutes and back to mobile phase A in 1 minute was used for separation of cardiolipin, phosphatidylcholine (PC), and phosphatidylethanolamine (PE) by UV detection (206 nm). Fractions were collected based on elution time of known standards, evaporated under a nitrogen stream, and resuspended in hexane, followed by the addition of 14% BF 3 -methanol and heating at 100°C for 30 minutes to obtain methyl esters for gas chromatography analysis of fatty acid composition. Fatty acid data are presented as % total fatty acids and D6D product/precursor ratios. given evidence for a link between membrane peroxidizability index (PI) and mammalian life span (19, 20) , the membrane PI was also calculated as: (% monoenoic × 0.025) + (% dienoic × 1) + (% trienoic × 2) + (% tetraenoic × 4) + (% pentaenoic × 6) + (% hexaenoic × 8).
Mitochondrial Respiration
State 3 (ADP-limited; 50 μM) and state 4 (leak) respiration rates were determined in freshly isolated mitochondria (75 μg protein) by high resolution respirometry (Oroboros Oxygraph, Innsbruck, Austria) with the saturating concentrations of pyruvate (5 mM) + malate (5 mM). Respiration studies were conducted at an initial oxygen concentration of 150 μM at 37°C in MiR06 respiration buffer containing (in mM) EgTA (0.5), MgCl 2 ·6 H 2 O (3), K-lactobionate (60), taurine (20) , KH 2 PO 4 (10), HEPES (20) , sucrose (110), 1 g/L BSA, 280 U/mL catalase, pH 7.4 (with KOH) (21) . ADP/O ratio was calculated by dividing the quantity of ADP by oxygen consumed during state 3 respiration as an index of oxidative phosphorylation efficiency. Relative protein expression of mitochondrial respiratory complexes I-V were determined by standard immunoblotting methods using an OXPHOS complex subunit antibody cocktail recognizing subunits from each of the five respiratory complexes (MitoSciences, #MS604, 1:2,000 dilution, incubated overnight at 4°C).
Mitochondrial H 2 O 2 Release
Mitochondrial ROS release was measured as H 2 O 2 in freshly isolated mitochondria (30 μg protein) using the fluorometric Amplex UltraRed probe (Molecular Probes; 59.1 μM) in the presence of horseradish peroxidase (0.12 U/mL) as previously described (22) . Fluorescence was measured in a microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA) with 560 nm excitation and 590 nm emission wavelengths. Mitochondria were incubated at room temperature in 50 mM KH 2 PO 4 , pH 7.4. H 2 O 2 production was monitored under state 4 conditions in the presence of oligomycin A (5 μg/mL) using succinate (5 mM) + rotenone (2.4 μM) (SROA; complex II linked) and malate (5 mM) + pyruvate (5 mM) (MPOA; complex I linked), over 30 minutes and presented as total H 2 O 2 produced minus background fluorescence using a H 2 O 2 standard curve (22) .
Mitochondrial Lipid Peroxidation
To assess the accumulation of lipoxidative stress to mitochondria, 30 μg of mitochondrial protein were immunoblotted for protein adducts of the lipid peroxidation product 4-hydroxynonenal (Calbiochem; catalog #393207; 1:2,000 dilution, incubated overnight at 4°C) followed by chemiluminescent detection using a UVP ChemiDoc imager (UVP, Upland, CA).
Echocardiography and Histology
Transthoracic echocardiography was performed under light (1.5%) isoflurane anesthesia immediately prior to and following the 4-week experimental period using a 12 MHz pediatric transducer connected to a Hewlett Packard Sonos 5500 Ultrasound. Short-axis 2D images of left ventricular (LV) end-diastolic and end-systolic areas (EDA and ESA, respectively) were obtained for assessment of LV chamber morphology and fractional shortening ((EDA − ESA)/ EDA) × 100). Data were averaged from five consecutive high-resolution cycles by the same experienced technician. Histology was conducted in 10-μm sections of small (2-3 mm 3 ) paraffin-embedded LV samples (n = 2-3/group) with Masson's trichrome stain for qualitative assessment of myocardial morphology and fibrosis.
Statistical Analyses
All data are presented as group means ± SE. Data were analyzed by 2 (Age) × 2 (Drug) analysis of variance to determine main and interaction effects with Tukey tests post hoc for determination of significant group differences. The Shapiro-Wilk test was used to determine normality of data grouped by independent variables (age and SC) prior to performing statistical analyses. Nonnormally distributed data were log transformed in order to meet the assumption of normality required for analysis of variance testing but are presented as raw mean ± SE values in the tables and figures for clarity. Within-group differences in echocardiography data from pretreatment to posttreatment were compared by paired t tests. All statistical analyses were performed using SPSS software (IBM SPSS Statistics 21) with statistical significance established a priori at p < .05.
Results
Phospholipid Fatty Acid Composition
Pilot studies in heart tissues obtained from the National Institute on Aging tissue bank confirmed a significant loss of 18:2n6 in cardiolipin and total cardiac phospholipids in aged versus young mice, which corresponded to an increase n3 and n6 PUFA product/precursor ratios routinely used as surrogate markers of D6D activity (Figure 1 and  Supplementary Table 1 ). In our experimental studies, old mice exhibited a similarly significant 21% lower proportion of 18:2n6 and elevated D6D product/precursor ratios in cardiac phospholipids from old versus young mice (Table 1) . Treatment with the D6D inhibitor reversed these effects, increasing 18:2n6 to above young control levels in both young and aged animals, and markedly decreasing dihomogamma-linolenic acid (20:3n6), DHA, and D6D product/ precursor ratios. A similar age-associated loss of 18:2n6 was observed in serum that was reversed by D6D inhibition ( Table 1 ), suggesting that changes in myocardial membrane composition may reflect systemic changes in peripheral (ie, hepatic) D6D activity that alter relative proportions of PUFAs supplied to the heart for phospholipid remodeling. Notes: AA = arachidonic acid; D6D = delta-6 desaturase; DgLA = dihomo-gamma-linolenic acid; DHA = docosahexaenoic acid; DPA = docosapentaenoic acid; PUFAs = polyunsaturated fatty acids. All data are means ± SEM of % total fatty acids or calculated D6D product/precursor indices (n = 4-6/group). PI = peroxidizability index calculated as in Methods section; n6/n3 ratio is the sum % total of all n6/n3 PUFAs detected in the sample. Main effects of aging, D6D inhibition (SC), and their interaction by analysis of variance are indicated by their respective p values. *p < .05.
Consistent with this notion, there was a trend for higher hepatic D6D protein expression in the aged versus young untreated mice (Supplementary Figure 1) , but this did not achieve statistical significance. Age-related changes in cardiolipin composition generally reflected those observed in total myocardial phospholipids, including a significant loss of 18:2n6 paralleled by reciprocal increases in AA, DHA, and multiple D6D activity ratios, all of which were reversed by D6D inhibition (Figure 2) . Effects of aging and D6D inhibition were nearly identical in SSM and IFM. The redistribution of LA, palmitic acid, and stearic acid for highly unsaturated DHA, AA, and dihomogamma-linolenic acid resulted in a significantly higher cardiolipin peroxidation index (PI) in mitochondria from aged hearts, which was reduced to below young control levels by treatment with the D6D inhibitor ( Figure 2E ). Significant main or interaction effects of D6D inhibition were seen for all fatty acids where significant paired group differences are indicated in Figure 2 as described in the legend.
Changes in mitochondrial PC and PE composition were distinct from those seen in cardiolipin, with predominant age-related effects being elevations in AA and Figure 2 . Delta-6 desaturase (D6D) inhibition reverses age-related cardiolipin remodeling. gas chromatographic analysis of cardiolipin fatty acid composition in subsarcolemmal mitochondria (SSM; A) and intermyofibrillar mitochondria (IFM; B) . Aging elicited significant increases in D6D product/precursor ratio in SSM (C) and IFM (D), as well as the cardiolipin peroxidizability index (E), all of which were reversed by D6D inhibition with SC-26196. *p < .05 vs young untreated; †p < .05 vs untreated cohort (same age). monounsaturated oleic (18:1n9) and/or vaccenic (18:1n7) acids, with decreases in 22:5n3 (docosapentaenoic acid) and DHA in both IFM (Supplementary Table 2a) and  SSM (Supplementary Table 2b ). These patterns of PUFA redistribution manifested as an increase in D6D product/ precursor ratios, reduced PI and an elevation in the n6/n3 ratio in both IFM and SSM. D6D inhibition markedly increased 18:2n6 in PE (~50%-80%) and PC (40%-113%) in both age groups and mitochondrial subpopulations and decreased AA and DHA to different extents depending on age and phospholipid class. Consequently, D6D inhibition decreased the PI and further increased the n6/n3 PUFA ratio in PC and PE in both mitochondrial subpopulations. Interestingly, D6D inhibition significantly increased the proportion of 18:1n9 only in old mice, particularly in PC and IFM, which may in part reflect the marked relative decreases in phospholipid DHA.
Animal Characteristics and Cardiac Structure/Function
Body weights were similar in young (31.8 ± 0.4 g) and old mice (31.4 ± 1.0 g) and were unaffected by treatment with the D6D inhibitor (30.8 ± 0.5 and 31.0 ± 0.9 in young and old, respectively). Heart weight was significantly greater in untreated old (179 ± 8 mg) compared with young mice (142 ± 3 mg) but was significantly lower in old mice treated with the D6D inhibitor (146 ± 3 mg; p < .05 vs old), suggesting an attenuation or reversal of age-associated cardiac hypertrophy. Consistent with this observation, echocardiography revealed a 12% reduction in LV end-diastolic area in old mice treated with the D6D inhibitor (p < .01; Figure 3A ), which was paralleled by amelioration of a 27% higher heart/body weight in old versus young untreated mice ( Figure 3B ). D6D inhibition prevented a 20% decline in LV fractional shortening resulting in part from a 32% increase in end-systolic area in untreated old mice during the 4-week study, indicating a preservation of LV contractile function in aged hearts. Qualitative histological assessment of LV morphology in a subset of samples from each group revealed fewer instances of perivascular and interstitial fibrosis in treated versus untreated old mice ( Figure 3C ), but insufficient tissue was available for a reliable quantitative assessment for cell morphology or tissue collagen deposition. No significant effects of D6D inhibition were seen on cardiac morphology or function in young mice. Figure 3 . Delta-6 desaturase (D6D) inhibition attenuates age-related cardiac hypertrophy contractile dysfunction. (A) Echocardiography revealed left ventricular dilatation (increased LV end-diastolic area) and systolic dysfunction (decreased fractional shortening and reduced end-systolic area) in old compared with young mice, which was prevented or reversed by D6D inhibition. *p < .05 vs pretreatment values within the same group. (B) Heart/body weight ratio was elevated in old untreated mice (−SC; n = 6), but similar to young in old mice treated with the D6D inhibitor (+SC; n = 6). *p < .05 vs young untreated; †p < .05 vs old untreated. (C) Representative images of Masson's trichrome stained LV sections from each of the experimental groups (n = 2-3/group; scale bar = 100 μm).
Mitochondrial Respiration
Significant main (suppressive) effects of aging on mitochondrial state 3 (phosphorylating) respiratory capacity, respiratory control, and oxidative phosphorylation efficiency (ADP/O) were seen in IFM but not in SSM (Figure 4 ). D6D inhibition had no effect on respiratory parameters except for a significant increase in ADP/O in old SSM. No significant effects of aging or D6D inhibition were seen on the protein contents of respiratory complex subunits in IFM ( Figure 4E and Supplementary Figure 2) .
Mitochondrial H 2 O 2 Release and Lipid Peroxidation
No effects of aging or D6D inhibition were seen on mitochondrial H 2 O 2 release from IFM or SSM when pyruvate + malate were provided as substrates ( Figure 5A ). Supplying electrons directly to respiratory complex II with succinate + rotenone substantially increases H 2 O 2 release from intact mitochondria by driving oxidant production from the Q o center of Complex III directed toward the intermembrane space where it can react with the Amplex Red substrate (23) . Under these conditions, a significant main effect of aging on mitochondrial H 2 O 2 release was seen in both mitochondrial subpopulations ( Figure 5B ). However, this effect was not modified by D6D inhibition. Despite significant changes in mitochondrial phospholipid peroxidation index, no effects of aging or D6D inhibition were seen on mitochondrial 4-hydroxynonenal-protein adducts ( Figure 5C ).
Discussion
The primary aim of this investigation was to determine if inhibition of essential PUFA metabolism by D6D would ameliorate age-related compositional changes in cardiac cardiolipin, thereby modulating mitochondrial function in the aged heart. Cardiolipin is a dimeric tetraacyl phospholipid found exclusively in mitochondria, where it provides essential structural and functional support to proteins involved in oxidative phosphorylation (13) . The majority of cardiolipin molecular species in the healthy mammalian heart contain four LA acyl chains. This LA enrichment is attenuated with aging (8, 17) and in age-related diseases such as heart failure (14), which has been suggested as a potential contributor to mitochondrial dysfunction associated with these conditions. It is well established that the compositional uniformity of cardiolipin results from a series of deacylation/reacylation reactions following de novo biosynthesis in mitochondria (13, 24) , but the mechanism of impaired LA enrichment in aging and age-related diseases has remained unclear. It was recently suggested that LA enrichment of cardiolipin may arise from an enzymatic equilibrium distribution of fatty acids exchanged between multiple phospholipid species (25) . Consistent with this notion, we hypothesized that bioavailability of LA may be reduced in the aged heart due to the actions of D6D and downstream desaturase and elongase enzymes, based on consistent evidence that the loss of LA is matched by increases in long-chain products of the D6D pathway (ie, AA and DHA). Indeed, our studies demonstrated reversal of this signature PUFA redistribution pattern in cardiolipin from aged mice following systemic D6D inhibition, increasing LA to levels greater than untreated young animals and reducing long-chain PUFAs to near or below that of untreated young mice. A similar pattern of reversal was seen in total myocardial and serum phospholipids, further indicating that changes in cardiolipin composition are reflective of a global redistribution of membrane PUFAs in the heart secondary to changes in systemic D6D activity. However, although similar patterns of PUFA redistribution (ie, altered D6D product/precursor ratios) were seen in mitochondrial PE and PC with aging and D6D inhibition, significant age-related reductions in LA were not seen in these phospholipid species. Therefore, it should be emphasized that in addition to the influence of PUFA bioavailability, specific phospholipase or acyltransferase enzymes not investigated in this study play an important role in generating distinct fatty acid compositions of PC, PE, and cardiolipin.
Detailed explanation of how aging and D6D inhibition elicit the complex patterns of fatty acid remodeling observed in myocardial phospholipids is beyond the scope of this investigation. However, the novel findings of our study merit some additional discussion in this context. For reasons that are unclear, LA and DHA represent the vast majority of PUFAs present in cardiac and mitochondrial phospholipids, accumulating to varying extents based Figure 5 . Mitochondrial oxidative stress. Mitochondrial H 2 O 2 release from subsarcolemmal mitochondria (SSM) and intermyofibrillar mitochondria (IFM) isolated from control (white bars) and SC-26196 treated mice (black bars) using malate + pyruvate (A; n = 6) or succinate + rotenone (B; n = 6) as substrates under state 4 (oligomycin-induced) conditions. (C) Densitometry and representative blotting of mitochondrial 4-hydroxynonenal-protein adducts from IFM (n = 6). All data are means ± SEM.*p < .05 for main effect of aging.
on their bioavailability and the phospholipid class (26) . Moreover, these PUFAs readily displace one another and other fatty acids in phospholipids, such that changes in one typically results in reciprocal changes in the other, perhaps along with relative changes in other abundant fatty acids (eg, 18:1 and 18:0) (8,10,14,16,26) . Inhibition of D6D amplifies this phenomenon, presumably by increasing cellular bioavailability of LA (D6D substrate) and decreasing that of DHA (D6D product), with congruent but comparatively minor effects on their respective PUFA derivatives (20:3n6, AA) and precursors (18:3n3, 22:5n3) that incorporate into phospholipids to a much lesser degree. Consequently, D6D inhibition elicits broad effects on membrane composition, including marked changes in the n6/n3 PUFA ratio and unsaturation index simply by altering levels of LA and DHA.
An increase in D6D activity would be expected to have the opposite effect, similar to what is seen in the aged compared with young heart in this study. However, the link between D6D activity and myocardial phospholipid remodeling in aging is not entirely clear. Microsomal D6D activity is extremely low in the heart and was not assessed in this study but has been reported to decrease slightly with age (27) . However, the rat heart is incapable of endogenous synthesis of DHA (28); therefore, changes in cardiac phospholipid composition may at least partially reflect changes in serum phospholipids supplied to the heart, derived primarily from the liver. Studies evaluating the effect of aging on hepatic D6D activity have produced variable results depending on the methods employed and outcomes assessed (29) (30) (31) ; however, most have shown that enzymatic activity in liver microsomes is reduced or unchanged with advancing age. Nevertheless, the present study supports a pivotal influence of this enzyme on age-related changes in myocardial and serum phospholipid composition, despite no significant change in hepatic enzyme expression. We speculate that posttranslational regulation of D6D activity, likely in conjunction with other lipid metabolism and phospholipid remodeling enzymes in the heart, liver, or both, orchestrate the complex age-related changes observed in cardiac mitochondrial membrane composition.
Reversal of cardiolipin remodeling with D6D inhibition provided an unprecedented opportunity to elucidate the functional implications of this phenomenon on aged cardiac mitochondria. The extent to which aging in the absence of overt pathology elicits cardiac mitochondrial dysfunction is somewhat controversial and is at least partially dependent on the models and methods employed (4, 5, (32) (33) (34) . We sought to extend information in the area by investigating effects on the two spatially and functionally distinct subpopulations of mitochondria present in cardiomyocytes. As previously reported in rats (5), significant respiratory dysfunction was only seen in IFM of aged mice in our study, manifesting as a main effect of aging to reduce the capacity (state 3), control (respiratory control ratio), and efficiency (ADP/O) of oxidative phosphorylation. These changes occurred despite no significant changes in respiratory enzyme protein expression, suggesting a possible role of altered membrane composition. However, D6D inhibition had no effect on these parameters in aged IFM, despite reversing age-related patterns of phospholipid PUFA remodeling. Moreover, similar age-related compositional changes were seen in cardiolipin, PC, and PE from both IFM and SSM, despite no significant changes in state 3 or state 4 respiration in SSM, and D6D inhibition significantly improved phosphorylation efficiency in aged SSM without effects on any other groups. The mechanisms and (patho)physiological implications of these divergent effects of aging and D6D inhibition on cardiac mitochondrial subpopulations are unclear and warrant further investigation. However, the existence of these findings despite relatively uniform effects on SSM and IFM phospholipid composition suggests that the age-related redistribution of membrane PUFAs does not exert a major independent influence on mitochondrial respiratory function in the aged heart, at least as assessed in isolated mitochondria. Recently, Picard and colleagues (35) reported that age-related impairment of muscle mitochondrial function demonstrated in isolated organelles is not seen to the same extent when evaluating the same parameters in permeabilized muscle fibers, suggesting that the mitochondrial isolation procedure or experimental conditions may influence the results obtained from aged myocytes. Whether changes in mitochondrial membrane composition influence the function of cardiac mitochondria in situ was not assessed in this study and remains an interesting area for future investigation.
Mitochondria may also contribute to cardiac aging by increasing release of ROS from the respiratory chain, leading to an accumulation of oxidative damage to cellular components (4, 33) . Exchange of LA for long-chain unsaturated PUFAs in cardiolipin has been associated with increased mitochondrial ROS release in other models (36, 37) ; therefore, the similar remodeling pattern observed in aged mitochondria may also enhance ROS release and oxidative stress. We observed significant main effects of aging on H 2 O 2 release from both SSM and IFM in the present study during nonphosphorylating (oligomycin A-inhibited) maximal succinate-supported respiration, indicating a greater capacity to release ROS from intact mitochondria. However, D6D inhibition had no effect on ROS release capacity in young or old mitochondria, arguing against a primary influence of mitochondrial phospholipid remodeling on this process.
Despite evidence for a greater capacity for mitochondrial ROS release with aging, we did not observe a significant increase in mitochondrial lipoxidative stress assessed by levels of 4-hydroxynonenal-protein adducts in mitochondria. This was surprising, as the higher unsaturation (or "peroxidizability") index of mitochondrial phospholipids alone would be expected to promote accumulation of lipid peroxidation species (10, 11, 20) . However, at least two other studies have demonstrated that greater incorporation of highly unsaturated fatty acids into membrane phospholipids does not necessarily elicit the increase in lipid peroxidation predicted by their PI in the absence of pathology (38, 39) . Nevertheless, it remains possible that other aldehyde species or derivatives of lipid peroxidation not examined in this study may be differentially affected by the observed changes in membrane PUFA composition.
Importantly, although the capacity for aged mitochondrial to release ROS under fully reduced (state 4) conditions was elevated in this study, this does not necessarily indicate that ROS production or release is elevated in vivo. Although evidence supporting greater cardiac mitochondrial oxidative damage in aging is controversial (40) , enhanced susceptibility to injury following acute oxidant stress (eg, ischemia) is more consistent (41) . Therefore, it is plausible that age-related unsaturation of membrane phospholipids predisposes the heart to oxidative injury from ROS but is not sufficient to promote oxidative stress in the absence of pathogenic stimuli.
Although reversal of phospholipid remodeling by D6D inhibition was not associated with improved mitochondrial function, the marked attenuation of cardiac hypertrophy and contractile dysfunction indicates a potently protective effect of D6D inhibition on the aged heart. Fractional shortening declined to ~52% in untreated aged mice but was maintained near young/pretreatment with D6D inhibition. This suggests that D6D activity or associated changes in myocardial membrane composition may contribute to the early transition from "compensated" cardiac hypertrophy to the progressive decline in contractile function associated with an increased risk of heart failure with aging (1,2). The mechanism of this effect will require further investigation but may involve reduced biosynthesis of AA and its eicosanoid derivatives. A proportional loss of LA is the most marked age-related change in myocardial and serum phospholipid composition. The reversibility of this effect by D6D inhibition implicates the conversion of LA into downstream PUFA desaturation/elongation products, the most prominent being AA. However, reciprocal increases in phospholipid AA were not seen to the same magnitude as LA losses in the present study. Importantly, PUFAs must be hydrolyzed from phospholipids by phospholipase A 2 in order to react with desaturase, elongase, and oxygenase enzymes, followed by their reestification to phospholipids by acyltransferase enzymes with varying substrate specificities (42) . The effect of aging on the activities of these enzymes is beyond the scope of this study; however, it is plausible that the blunted increase in phospholipid AA reflects greater amounts of "free" AA and/or its metabolism by enzymatic and nonenzymatic oxidation pathways capable of generating a host of bioactive eicosanoid species (43, 44) . Enhanced metabolism of AA though these pathways in cardiomyocytes promotes maladaptive cardiac hypertrophy and contractile dysfunction in transgenic mice (45, 46) and activates extracellular receptor kinase signaling and hypertrophy in cardiomyocytes (47, 48) . Therefore, increased flux of LA through the D6D pathway may drive pathogenic eicosanoid production and contribute to myocardial remodeling in aging.
In summary, this study demonstrates that LA enrichment of cardiolipin can be restored in the aged heart by inhibiting the D6D pathway, implicating PUFA metabolism as an important determinant of cardiolipin composition in the heart. Phospholipid remodeling does not appear to influence mitochondrial respiration or oxidant production in the aged heart but may reflect global changes in PUFA metabolism that appear to have important effects on myocardial remodeling and function. Future studies are needed to explore the mechanisms of this effect and perhaps other (patho)physiological manifestations of phospholipid remodeling in aging and related pathologies.
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